和鉑醫藥-B(02142.HK)共同開發項目在內地針對哮喘試驗完成向首名患者給藥
和鉑醫藥-B(02142.HK)公佈,HBM9378,一款針對胸腺基質淋巴細胞生成素的全人源抗體,用於治療中重度哮喘,在中國的I期試驗完成向首名受試者給藥。
和鉑醫藥指,HBM9378乃公司與科倫博泰開展的共同開發項目,二者共同享有HBM9378的全球權利。根據公司與科倫博泰之間的戰略協作及許可協議,雙方將共同探索單克隆抗體以及抗體偶聯物的創新療法。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.